Weiner, L.M., Dhodapkar MV, and Ferrone S.: Monoclonal antibodies for cancer immunotherapy. Lancet 2009, 373:1033–1040.
Weng, W.K., and Levy, R.: Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk. Lymphoma 2009, 50:723–727.
16-18 Enhancing the immune response to tumors by vaccination holds promise for cancer prevention and therapy.
Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., et al.: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363:411–422.
Kenter, G.G., Welters, M.J., Valentijn, A.R., Lowik, M.J., Berends-van der Meer, D.M., Vloon, A.P., Essahsah, F., Fathers, L.M., Offringa, R., Drijfhout, J.W., et al.: Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
N.Engl. J. Med. 2009, 361:1838–1847.
References.
Mao, C., Koutsky, L.A., Ault, K.A., Wheeler, C.M., Brown, D.R., Wiley, D.J., Alvarez, F.B., Bautista, O.M., Jansen, K.U., and Barr, E.: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 2006, 107:18–27.
Palucka, K., Ueno, H., Fay, J., and Banchereau, J.: Dendritic cells and immunity against cancer. J. Intern. Med. 2011, 269:64–73.
Vambutas, A., DeVoti, J., Nouri, M., Drijfhout, J.W., Lipford, G.B., Bonagura, V.R., van der Burg, S.H., and Melief, C.J.: Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005, 23:5271–5280.
16-19 Checkpoint blockade can augment immune responses to existing tumors.
Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S,J,, Millenson, M.M., Cattry, D., Freeman, G.J., et al.: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015, 372:311–319.